Kelly Pugh

Kelly Pugh

Auto-generated profile, based on publicly available information

Kelly Pugh

Division of Hematology, The Ohio State University Comprehensive Cancer Center/James Cancer Hospital, The Ohio State University, Columbus, OH

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2025 in Blood
Verified
Journal Article
Open access
UBUma Borate
Uma Borate
KPKelly Pugh
Kelly Pugh
AWAllyson Waller
Allyson Waller
RWRina Li Welkie
Rina Li Welkie
YHYing Huang
Ying Huang
AZAmer M. Zeidan
Amer M. Zeidan
Excessively restrictive inclusion and exclusion criteria in clinical trials are one of many barriers to clinical trial enrollment for patients with myelodysplastic syndromes/neoplasms (MDSs). Many organizations are developing efforts to increase clinical trial eligibility; yet, several recent publications focused on patients with MDS suggest that many patients with this disease may be excluded from clinical trials unnecessarily. Clinical trial eligibility should reflect the phase of the study and risks of the agent being studied. Phase 3 trials should be less restrictive than early-phase trials to represent the real-world population as closely as possible. We hypothesize that many clinical trials, particularly phase 3 trials, have unnecessarily restrictive eligibility criteria. This study aims to evaluate the most common eligibility criteria according to phase of trial and to determine whether criteria correspond with drug safety signals. We identified MDS clinical trials registered on ClinicalTrials.gov from 1 January 2000 to 1 September 2023 and analyzed the eligibility criteria of 191 therapeutic MDS trials. We found that categorical inclusion and exclusion criteria are remarkably similar in representation across trial phases. Additionally, only 13% of trials are concordant with drug safety signals, suggesting that the eligibility criteria are often arbitrary. On behalf of the icMDS (International Consortium for Myelodysplastic Syndromes), an association of international MDS experts, we provide a position statement on restrictive eligibility criteria for MDS clinical trials that should be avoided with the aim of removing barriers to clinical trial enrollment.

13 November 2026 in Blood
Verified
Journal Article
Closed access
ABAndrew M. Brunner
Andrew M. Brunner
TGTed M. Getz
Ted M. Getz
KPKelly Pugh
Kelly Pugh
JBJan Bewersdorf
Jan Bewersdorf
TKTariq Kewan
Tariq Kewan
AZAmer M. Zeidan
Amer M. Zeidan
Variability in how clinical trial elements are reported can hinder accurate interpretation and comparison of trial results. Here, we systematically analyzed published manuscripts of therapeutic clinical trials in myelodysplastic syndromes/neoplasms (MDS) focusing on how key data elements were reported and made recommendations on how to improve this reporting. We included peer-reviewed full text manuscripts that reported results of clinical trials in MDS and were published between January 1, 2015 to December 31, 2024. We analyzed the presence or absence of several pre-determined key reporting elements and then synthesized these data to evaluate for consistency across manuscripts. We identified substantial variability in descriptions of patient characteristics, as well as the definitions used for response criteria. For example, baseline ANC was reported in only 16% of lower-risk MDS studies and 23% of higher-risk MDS studies, while baseline bone marrow blast percentage was reported in only 55% of higher-risk MDS manuscripts. In addition, response endpoints lacked standardization, with six unique definitions of RBC transfusion independence identified in lower-risk MDS trials and seven different definitions of overall response rate identified in higher-risk MDS trials. Informed by the results of this analysis, we then performed a modified-Delphi process for members of the International Consortium for MDS (icMDS) to develop consensus-based recommendations for consistent and accurate reporting of MDS clinical trial results. We advocate that these recommendations serve as benchmarks and templates for clinical trial reporting in MDS to improve interpretability and comparison of results.